Phase IV Commitments Are Increasingly Delayed, FDA Report Finds
Executive Summary
The rate of delayed postmarketing commitments has increased since 2005, according to data provided in FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies.
You may also be interested in...
Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds
Displaying a trend policy-makers hope to reverse through provisions in the FDA Amendments Act, FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Post-marketing Commitment Studies" shows that the rate of delayed post-marketing commitments in 2007 has again slightly increased
Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds
Displaying a trend policy-makers hope to reverse through provisions in the FDA Amendments Act, FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Post-marketing Commitment Studies" shows that the rate of delayed post-marketing commitments in 2007 has again slightly increased
New Risk Management Landscape For Drugs Offers Fertile Ground For CROs
The coming year could see the first use of the enhanced safety powers created by the FDA Amendments Act, but 2008 is certain to see a shift in the pharmaceutical industry's development approach as it grapples with the need for more safety data